Greenway Reports Expanded International Cannabis Sales

• Date: May 28, 2026 (Most Recent)
• Headline: Greenway Reports Expanded International Cannabis Sales
• Core Update: International sales now constitute approximately 50% of total company sales volume.
• Strategic Context: International shipments commenced in late 2024; management has methodically increased exposure to global medical cannabis markets through strategic partnerships.
• Pricing Dynamics: Management believes international medical cannabis markets offer stronger realized pricing per gram compared to the domestic market, supporting improved revenue potential and diversification.
• Product Development: Several new cannabis cultivars have been advanced specifically for international medical opportunities; genetics are being assessed for flower quality, cannabinoid profiles, terpene expression, and repeatable THC results.
• Operational Model: Combines large-scale greenhouse production with a focus on premium flower quality to maintain cost control and operational consistency across 2.5 acres of active cultivation.

• Validation of Strategy: The news confirms the trajectory established in previous quarters (Dec 2025 Q2 results, Jan 2026 Year Review) where international expansion was highlighted as a key growth driver.
• Margin Implications: Achieving a 50% mix with higher-priced international markets should theoretically support gross margins, building on the improvement from 15% (Q3 FY2024) to 29% (Q3 FY2025).
• Incremental Nature: While significant for diversification, this is an operational milestone rather than a sudden structural change like a takeover or new major investor. The market likely anticipated continued growth given the Q3 financial results released in February 2026.
• Revenue Quality: The shift to international markets reduces reliance on domestic pricing pressure, which has been a headwind for many cannabis producers. However, execution risk remains regarding logistics and regulatory compliance in multiple jurisdictions.
• Capital Efficiency: No new capital expenditure is required to activate the additional cultivation capacity mentioned in previous reports (Jan 2026), preserving cash flow.

• Company: Greenway (CSE Listed).
• Flagship Project: Large-scale greenhouse cultivation facility focused on premium medical cannabis flower.
• Capacity: 2.5 acres of active cultivation; additional capacity built out in 2025 increasing potential production capability by >75% without new capex.
• Market Focus: Shift from domestic to international medical markets (Europe, Australia, UK).
• Product Strategy: Tailoring cultivars specifically for international opportunities with consistent cannabinoid profiles and terpene expression.